Fallopian Tube Cancer Clinical Trials in Pittsburgh, Pennsylvania

8 studies are recruiting for fallopian tube cancer in Pittsburgh, Pennsylvania right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

   This study is researching an experimental drug called ubamatamab, also referred to as "study drug". The study is focused on participants who have advanced ovarian cancer. The aim of the study is to see how safe, tolerable, and effective the study drug is on its own and in combination with other ant…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center, Magee-Womens Hospital, Pittsburgh, Pennsylvania

   Locations

   56 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06787612 on ClinicalTrials.gov

2. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Allegheny Health Network West Penn Hospital ( Site 0099), Pittsburgh, Pennsylvania

   Locations

   196 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

3. Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

   The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with pla…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   AHN West Penn Hospital, Pittsburgh, Pennsylvania

   Locations

   33 in total

   Run by

   Genelux Corporation

   See if you can join NCT05281471 on ClinicalTrials.gov

4. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

   This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Allegheny Health Network, Pittsburgh, Pennsylvania

   Locations

   66 in total

   Run by

   Genmab

   See if you can join NCT05579366 on ClinicalTrials.gov

5. Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

   This is a Phase 2, open-label, global, multi-arm study to evaluate efficacy and safety of relacorilant in combination with other treatments in patients with gynecological cancers.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   127, Pittsburgh, Pennsylvania

   Locations

   49 in total

   Run by

   Corcept Therapeutics

   See if you can join NCT06906341 on ClinicalTrials.gov

6. An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

   The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   UPMC Magee-Women's Hospital, Pittsburgh, Pennsylvania

   Locations

   6 in total

   Run by

   University of Colorado, Denver

   See if you can join NCT05887609 on ClinicalTrials.gov

7. ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer

   This Phase 2, open label, study with safety lead in of oral talazoparib in combination with ZEN003694 given daily in 28-day cycles will enroll patients with recurrent ovarian, fallopian tube or primary peritoneal carcinoma.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

   Run by

   Alexander B Olawaiye, MD

   See if you can join NCT05071937 on ClinicalTrials.gov

8. A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

   This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. Th…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania

   Locations

   5 in total

   Run by

   Regeneron Pharmaceuticals

   See if you can join NCT06469281 on ClinicalTrials.gov